<mets:mets xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" LABEL="Eprints Item" OBJID="eprint_64510" xmlns:mets="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mets:metsHdr CREATEDATE="2026-06-02T20:57:41Z"><mets:agent ROLE="CUSTODIAN" TYPE="ORGANIZATION"><mets:name>Arxiv Universal Publishings</mets:name></mets:agent></mets:metsHdr><mets:dmdSec ID="DMD_eprint_64510_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:titleInfo><mods:title>SOMATOTROP YETISHMOVCHILIGI BOR BOLALARDA SINTETIK SOMATOTROPIN ANALOGLARI FONIDA BO’Y O'SISH DINAMIKASI</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Zubayda</mods:namePart><mods:namePart type="family">Xalbayeva</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Somatotrop yetishmovchiligi (SY), shuningdek, growth hormone deficiency (GHD) nomi bilan ma'lum, bolalarda o'sish gormonining yetarli darajada ishlab chiqarilmasligi bilan bog'liq endokrin kasallik bo'lib, bu holat bo'y o'sishining sekinlashuviga, yakuniy bo'yining past bo'lishiga va psixososial rivojlanishdagi muammolarga olib keladi. Sintetik somatotropin analoglari, xususan rekombinant inson o'sish gormoni (rhGH), bu kasallikni davolashda asosiy usul hisoblanadi va bolalarning bo'y o'sish dinamikasini sezilarli darajada yaxshilaydi. Ushbu obzor maqola PubMed, PMC, Scopus va boshqa yuqori indekslangan ma'lumotlar bazalaridagi so'nggi sistematik obzorlar, meta-tahlillar va klinik tadqiqotlardan foydalangan holda, rhGH ning bolalardagi bo'y o'sish dinamikasiga, jumladan o'sish tezligi (height velocity, HV), bo'y standart deviyatsiya skori (height SDS, HSDS) va yakuniy kattalar bo'yiga (adult height, AH) ta'sirini batafsil tahlil qiladi. Natijalar shuni ko'rsatadiki, davolashning birinchi yilida HV o'rtacha 8-12 sm/yilga yetishi mumkin, keyingi yillarda esa 4-7 sm/yilga pasayadi, bu normal o'sish tezligiga yaqinlashadi. Yakuniy AH SDS treated guruhda o'rtacha -2,5 dan -0,3 ga yaqinlashadi, bu normal diapazonga (0 ± 2 SDS) yaqinlashishni anglatadi va untreated guruhga nisbatan 4-8 sm farqni ta'minlaydi. Yuqori dozalar (0,025-0,07 mg/kg/hafta) samaraliroq bo'lib, ammo individual omillar, masalan, yosh (davolashni erta boshlash yaxshiroq natija beradi), boshlang'ich bo'y SDS, pubertal holat, suyak yoshi (bone age), metabolik ko'rsatkichlar (insulin qarshiligi, tiroid gormonlari, hemoglobin, IGF-1 darajasi) va genetik faktorlar (masalan, GH1 geni mutatsiyalari) ta'sir qiladi. Davolash xavfsizligi yuqori, jiddiy nojo'ya ta'sirlar (masalan, intrakranial gipertenziya, neoplazma rivojlanishi) kam (1-2% dan kam), ammo in'ektsiya joyidagi lokal reaktsiyalar va vaqtinchalik IGF-1 oshishi tez-tez uchraydi. Ushbu obzor rhGH ning qisqa muddatli (birinchi 6-12 oy) va uzoq muddatli (5-10 yil) natijalarini, shuningdek, kunlik va haftalik (pegylated) dozalash usullarini taqqoslaydi, GHD va idiopathic short stature (ISS) o'rtasidagi farqlarni ko'rib chiqadi (GHD da natijalar 20-30% yaxshiroq). Bundan tashqari, davolashning farmakoekonomik jihatlari (xarajat-samaradorlik), monitoring usullari (IGF-1 va IGFBP-3 o'lchovlari, suyak yoshi rentgeni) va kelajakdagi tadqiqot yo'nalishlari (gen terapiyasi, yangi LAGH formulalari) muhokama qilinadi. Obzor 1990-2025 yillardagi 100 dan ortiq tadqiqotni qamrab oladi va pediatrik endokrinologlar uchun klinik amaliyot bo'yicha batafsil tavsiyalar beradi, jumladan dozani individualizatsiya qilish va davolash muddatini optimallashtirish.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-12-15</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Center for Tech and Media Research</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mets:xmlData></mets:mdWrap></mets:dmdSec><mets:amdSec ID="TMD_eprint_64510"><mets:rightsMD ID="rights_eprint_64510_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:useAndReproduction>
<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by its own author:</strong>
In self-archiving this collection of files and associated bibliographic
metadata, I grant Arxiv Universal Publishings the right to store
them and to make them permanently available publicly for free on-line.
I declare that this material is my own intellectual property and I
understand that Arxiv Universal Publishings does not assume any
responsibility if there is any breach of copyright in distributing these
files or metadata. (All authors are urged to prominently assert their
copyright on the title page of their work.)</p>

<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by someone other than its
author:</strong> I hereby declare that the collection of files and
associated bibliographic metadata that I am archiving at
Arxiv Universal Publishings is in the public domain. If this is
not the case, I accept full responsibility for any breach of copyright
that distributing these files or metadata may entail.</p>

<p xmlns="http://www.w3.org/1999/xhtml">Clicking on the <em>Deposit Item Now</em> button indicates your agreement to these
terms.</p>
    </mods:useAndReproduction></mets:xmlData></mets:mdWrap></mets:rightsMD></mets:amdSec><mets:fileSec></mets:fileSec><mets:structMap><mets:div DMDID="DMD_eprint_64510_mods" ADMID="TMD_eprint_64510"></mets:div></mets:structMap></mets:mets>